Study |
Subjects |
Design |
Dose |
Outcomes |
Duan K, et al.191
China
|
10
Severe disease, ICU no MV
|
Pilot study, single center. Compared to historic control group
|
200 ml CP with neutralizing antibody titers >1:640
|
Increase in neutralizing antibodies. Improvement of symptoms. Increase
in oxyhemoglobin saturation at d 3. Decrease CRP. No severe side
effects. Reduction of deaths compared to historic control (p
0.001)
|
Shen C, et al.277
China
|
5
Critical disease, all in ICU + MV
|
Uncontrolled. Case series, single center
|
400 ml CP with titer > 1:1000 and neutralizing antibody
titer >40
|
4/5: ARDS resolved within 12 d
5/5: Pao2/Fio2 increased within 12 d
5/5: SARS-CoV-2 RNA load negative at d 12
3/5: discharged from hospital at date of publication (51-55 d post
infusion)
|
Zhang B, et al.278
China
|
4
Critical disease, ICU + MV
|
Uncontrolled. Case series
|
200 - 400 ml CP
(does not specify neutralizing antibody titer)
|
4/4 clinical improvement and able to extubate
3/4 discharged from hospital at date of publication (24-33 d post
infusion)
|
Ahn JY, et al.279
South Korea
|
2
Critical disease, ICU + MV
|
Case series
|
250 ml, 2 doses 12 h apart, (does not specify neutralizing antibody
titer)
|
Radiological and clinical improvement.
Decrease in viral load
|
Ye M, et al.280
China
|
6
Non-critically ill
|
Case series
|
200 - 600 ml CP
(does not specify neutralizing antibody titer)
|
Radiological and clinical improvement
|
Zeng QL et al.281
China
|
21 ICU patients
6: active CP
15: controls
|
Case series Non-randomized.Controls did not have a match for CP
|
200 - 400 ml CP
(does not specify neutralizing antibody titer)
|
Increase in viral clearance in the CP vs controls. [CP 5/5,
Controls 3/14 (p 0.005)]
Increase survival period in CP patients (p 0.029) but there was
high mortality in both groups, [CP 5/6, controls 14/15]
|
Schulman K. (PI)
USA
|
Estimated enrollment: 206 patients visiting the ED
|
Phase 2 trial. Randomized, double blinded, controlled. CP vs
placebo in adults with COVID-19 in an ED
|
200 - 600 ml CP with neutralizing antibody titers
>1:80
|
Stanford University
Ongoing
NCT04355767
|
Shoham S. (PI)
USA
|
Estimated enrollment: 150 subjects exposed to COVID-19
|
Phase 2 trial. Randomized, triple blinded, controlled. CP vs
placebo. Adults in close contact exposure to a person with COVID-19
within 96 h of enrollment (and 120 h of receipt of plasma)
|
200 ml CP with neutralizing antibody titers >1:64
|
Johns Hopkins University
Ongoing
NCT04323800
|
Perotti C. (PI)
Italy
|
Estimated enrollment: 46 COVID-19 patients with moderate-severe ARDS for
< 10 d and need for MV
|
Longitudinal non-randomized non-controlled
|
250-300 ml of CP 3 times/d over 5 d
(neutralizing antibody titer not specified)
|
Foundation IRCCS San Matteo Hospital
Ongoing
NCT04321421
|
Menichetti F. (PI)
Italy
|
Estimated enrollment: 126 COVID-19 patients hospitalized due to
pneumonia with PaO2/FiO2 ratio 200-350
but not in MV
|
Phase 2 Trial. Multicenter prospective randomized open-label trial (CP
vs standard therapy
|
200 ml of CP
(neutralizing antibody titer not specified)
|
Azienda Ospedaliero, Universitaria Pisana
Ongoing
NCT04393727
|